{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:58:23Z","timestamp":1788872303559,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fonds de la Recherche en Sant\u00e9 du Qu\u00e9bec"},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["MOP-67183"],"award-info":[{"award-number":["MOP-67183"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["CSU-105837"],"award-info":[{"award-number":["CSU-105837"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.pnpbp.2011.05.011","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T06:19:41Z","timestamp":1306304381000},"page":"1695-1698","source":"Crossref","is-referenced-by-count":29,"title":["Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders"],"prefix":"10.1016","volume":"35","author":[{"given":"Raouf","family":"Igue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramatoulaye","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Stip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch-Hugo","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Kouassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.05.011_bb0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(98)00140-6","article-title":"Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration","volume":"37","author":"Akiyama","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pnpbp.2007.06.031","article-title":"The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma","volume":"32","author":"Bian","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00023210-200418030-00004","article-title":"Quetiapine: a review of its use in the management of schizophrenia","volume":"18","author":"Cheer","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/schbul\/16.1.57","article-title":"Diagnosis of alcohol use disorders in schizophrenia","volume":"16","author":"Drake","year":"1990","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0030","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00846549","article-title":"Measuring nicotine dependence: a review of the Fagerstr\u00f6m Tolerance Questionnaire","volume":"12","author":"Fagerstr\u00f6m","year":"1989","journal-title":"J Behav Med"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","article-title":"Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis","volume":"33","author":"Haack","year":"1999","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1006\/brbi.2001.0645","article-title":"In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research","volume":"15","author":"Hinze-Selch","year":"2001","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0050","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/diabetes.52.5.1104","article-title":"Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation","volume":"52","author":"Juge-Aubry","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200262050-00003","article-title":"Substance misuse in patients with schizophrenia","volume":"62","author":"Kavannagh","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00207450108986549","article-title":"Effect of risperidone on serum cytokines","volume":"111","author":"Kim","year":"2001","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/026988119901300405","article-title":"Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies","volume":"13","author":"Laruelle","year":"1999","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0085","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1572-0241.2005.41509.x","article-title":"Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease","volume":"100","author":"Latvala","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0920-9964(96)00029-1","article-title":"Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs","volume":"21","author":"Maes","year":"1996","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-977X(99)00062-0","article-title":"Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics","volume":"10","author":"Maes","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0110","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1523\/JNEUROSCI.23-16-06470.2003","article-title":"Endogenous interleukin-1 receptor antagonist mediates antiinflammatory and neuroprotective actions of cannabinoids in neurons and glia","volume":"23","author":"Molina-Holgado","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4603(98)00073-2","article-title":"Dual diagnosis: a review of etiological theories","volume":"23","author":"Mueser","year":"1998","journal-title":"Addict Behav"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1749-6632.2000.tb05410.x","article-title":"The immune system and schizophrenia: an integrative view","volume":"917","author":"M\u00fcller","year":"2000","journal-title":"Ann. N.Y. Acad Sci"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(97)00059-5","article-title":"A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?","volume":"26","author":"Naudin","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/070674370304800104","article-title":"Clinical aspects of substance abuse in persons with schizophrenia","volume":"48","author":"Negrete","year":"2003","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-199610000-00011","article-title":"Effects of clozapine on plasma cytokine and soluble cytokine receptor levels","volume":"16","author":"Pollm\u00e4cher","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0269881107083816","article-title":"Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy","volume":"22","author":"Potvin","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0150","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1185\/030079906X112561","article-title":"Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: an open-label trial","volume":"22","author":"Potvin","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0155","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11481-010-9247-2","article-title":"Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: mediators and traffic","volume":"6","author":"Rogers","year":"2011","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0165","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","article-title":"The soluble interleukin-2 receptor: biology, function, and clinical application","volume":"113","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psychres.2004.04.012","article-title":"Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients","volume":"134","author":"Sirota","year":"2005","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0175","series-title":"Measuring alcohol consumptions: psychosocial and biochemical methods","first-page":"41","article-title":"Timeline follow-back: a technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaut.2006.07.006","article-title":"Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited","volume":"27","author":"Strous","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.pnpbp.2011.05.011_bb0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-008-1447-6","article-title":"Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics","volume":"204","author":"Zhang","year":"2009","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611001679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611001679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T19:00:55Z","timestamp":1588791655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584611001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0278584611001679"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.05.011","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}